Guardant Health, Inc. (BMV:GH)

Market Cap	271.58B +181.4%
Revenue (ttm)	19.47B +39.6%
Net Income	-7.81B
EPS	-61.38
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33
Average Volume	1,039
Open	2,080.00
Previous Close	1,990.00
Day's Range	2,080.00 - 2,080.00
52-Week Range	820.00 - 2,080.00
Beta	n/a
RSI	74.22
Earnings Date	May 7, 2026

About Guardant Health

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transc...

• Founded: 2011
• Country: Mexico
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: GH

Financial Performance

In 2025, Guardant Health's revenue was $982.02 million, an increase of 32.88% compared to the previous year's $739.02 million. Losses were -$416.28 million, -4.61% less than in 2024.

Financial numbers in USD